Asset Details
Do you wish to reserve the book?
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Do you wish to request the book?
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015
Overview
In this trial, the addition of six cycles of docetaxel to androgen-deprivation therapy resulted in longer median progression-free and overall survival than that with ADT alone in patients with metastatic prostate cancer.
Regressions of metastatic prostate cancer were first documented in the 1940s and were achieved with surgical castration; subsequently, androgen-deprivation therapy (ADT) became the mainstay of therapy.
1
Attempts to improve the efficacy or decrease the treatment burden of ADT have included the use of antiandrogens alone, intermittent dosing of ADT, and the use of an antiandrogen combined with medical or surgical castration.
2
–
4
A meta-analysis revealed an increase in survival of 3 percentage points at 5 years with concurrent use of a nonsteroidal antiandrogen at the time of initiation of ADT.
2
However, resistance to ADT occurs in most patients, with the . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Androgen Antagonists - adverse effects
/ Androgen Antagonists - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Hormones
/ Humans
/ Male
/ Neutropenia - chemically induced
/ Oncology
/ Patients
/ Prostate-Specific Antigen - blood
/ Prostatic Neoplasms - drug therapy
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - pathology
/ Survival
